Correlation between PTPN11 gene mutations and congenital heart defects in Noonan and LEOPARD syndromes

A Sarkozy, E Conti, D Seripa, M C Digilio, N Grifone, C Tandoi, V M Fazio, V Di Ciommo, B Marino, A Pizzuti, B Dallapiccola

Noonan syndrome (MIM 163950), an autosomal domin-ant disorder with an estimated prevalence of 1/1000–2500 at birth, is characterised by short stature, facial anomalies, pterygium colli, and congenital heart disease. Although pulmonary valve stenosis with dysplastic leaflets, hypertrophic cardiomyopathy, and atrial septal defects (ASD) are the most common congenital heart defects in Noonan syndrome, a broad spectrum of cardiac phenotypes has been recognised. About half the affected individuals have PTPN11 gene mutations. This gene, which maps to chromosome 12q22-qter, encodes for the human SH2 domain containing protein tyrosine phosphatase (SHP2). PTPN11 gene mutations have also been detected in multiple lentigines/LEOPARD syndrome (multiple lentigines, ECG conduction abnormalities, ocular hypertelorism, pulmonary stenosis, abnormal genitalia, retardation of growth and sensorineural deafness; ML/LS, MIM 151100), in Noonan-like/multiple giant cell lesion syndrome (MIM 163953), in two families presumably affected by cardio-facio-cutaneous syndrome (CFCS, MIM 115190), but not in sporadic CFCS. The clinical and genetic heterogeneity of these disorders suggests a possible relation between different PTPN11 gene mutations and distinct clinical features. A genotype–phenotype correlation study in Noonan syndrome found an association between pulmonary stenosis and PTPN11 mutations. Our aim in this study was to screen a large cohort of patients with Noonan syndrome and ML/LS in order to expand the genotype–phenotype correlation analysis, with particular emphasis on cardiac diseases.

METHODS

Patients

Eighty four white Italian patients were recruited. Informed consent and family history were obtained from all subjects and their parents. Patients were ascertained by clinical geneticists and paediatric cardiologists. Noonan syndrome was diagnosed on the basis of the cardinal features delineated by Allanson—in particular short stature, congenital heart defects, broad or webbed neck, chest deformity, developmental delay of variable degree, cryptorchidism, and characteristic facies. For diagnosis of ML/LS, the presence of lentigiosis and café au lait spots was required, in combination with at least three of the cardinal features outlined by Yoron et al. Clinical assessment included family history, complete physical evaluation of dysmorphisms and malformations, anthropometric measurements, renal ultrasonography, and radiological studies. Standard karyotyping was normal in all patients.

Cardiac evaluation in all patients included preoperative chest x ray, ECG, and cross sectional and colour Doppler echocardiography. Pulmonary stenosis, pulmonary valve leaflet dysplasia, and hypertrophic cardiomyopathy were assessed using classical echocardiographic criteria. Cardiac catheterisation with angiography was undertaken in 51 patients as an aid to preoperative assessment, to attempt pulmonary valve dilatation, or to demonstrate left ventricular shape. The cardiac diagnoses were confirmed during cardiac surgery in 32 subjects.

The patients’ parents were examined for major or minor dysmorphisms and cardiac or extracardiac anomalies.
Noonan syndrome was diagnosed in 71 subjects, including one with pigmented villonodular arthrosynovitis, and ML/LS in 13. The study group included 44 females (52%) and 40 males (48%), ranging between 0.1 and 26 years (mean (SD), 8.4 (3.7) years). Seventy four patients were sporadic and 10 familial. One member from each family, presenting with the full blown phenotype, was included in the mutation screening and correlation analysis. Affected and unaffected parents and relatives were screened only after the identification of a PTPN11 gene mutation in the index case.

**Mutation screening**

PTPN11 gene coding regions and exon-intron boundaries, including about 50 base pairs (bp) upstream and downstream of the exons (GenBank Accession Number: NM_002834), were amplified by polymerase chain reaction (PCR) and analysed by single strand conformation polymorphism (SSCP; Genephor Unit; Amersham Pharmacia Biotech, Uppsala, Sweden). Anomalous fragments were sequenced by the Big Dye Terminator Abi Prism sequencing kit (Applied Biosystems, Foster City, California, USA), and run on an ABI PRISM 3100 genetic analyser automated sequencer (Applied Biosystems). Mutation hot spots were analysed by direct sequencing in patients with Noonan syndrome affected by pulmonary stenosis and in patients with ML/LS not associated with any anomalous mobility shifts on SSCP analysis of exon 8 and exons 7 and 12, respectively, before screening the rest of the gene.

**Statistical analysis**

All continuous variables were expressed as the mean (SD) for each measurement. Comparisons between patient groups were done using Fisher’s exact test, with a significance threshold of p < 0.05.

**RESULTS**

**PTPN11 mutation analysis**

Fourteen different missense mutations, including four novel changes, were detected in 34 patients, including 29 sporadic and five unrelated familial cases (fig 1, table 1). None of these mutations was found in 200 control chromosomes or in five unrelated familial cases (fig 1, table 1). None of the changes, were detected in 34 patients, including 29 sporadic and five unrelated familial cases (fig 1, table 1). None of the changes, were detected in 34 patients, including 29 sporadic and five unrelated familial cases (fig 1, table 1).

Noonan syndrome had 12 different PTPN11 mutations, 10 of which were located in the N-SH2 and PTP domains. Codon 308 was a mutation hot spot, which was a mutation hot spot only in patients with Noonan syndrome. Conversely, hypertrophic cardiomyopathy was more strictly associated with mutations in exons 7 and 12 (p = 0.01), a hot spot in ML/LS. The three patients with ASD had mutations in exon 3 (p = 0.013) within the N-SH2 domain. Although not statistically significant (p = 0.07), a positive trend was noted between mutations in the N-SH2 domain and congenital heart defects. In fact, congenital heart disease occurred in all patients with N-SH2 mutations (11/11), and in only 70% of those with PTP domain mutations (16/23) (table 1). No association was found between AVCD, MVA, and different domain mutations (table 1). Seven of 11 patients without congenital heart defects presented PTPN11 mutations, all within the PTP domain.

No significant difference was found in the prevalence of congenital heart defects between Noonan syndrome and ML/LS with PTPN11 mutations (87% (20/23) in Noonan syndrome; 64% (7/11) in ML/LS; p = 0.1). Among the Noonan syndrome patients with mutations, pulmonary
stenosis was the most common congenital heart defect (65%) and was associated with a codon 308 mutation hot spot (p = 0.03), while hypertrophic cardiomyopathy was detected only in the 15% of the individuals with congenital heart defects. Two of three Noonan syndrome patients without congenital heart defects harboured exon 13 mutations.

Among the ML/LS patients with mutations, the prevailing congenital heart defect was hypertrophic cardiomyopathy (71%), in association with mutation hot spots in exon 7 and 12, while pulmonary stenosis and AVCD occurred in single patients. Two of four ML/LS patients without structural congenital heart defects had atrioventricular conduction defects (fig 1, table 1).

<table>
<thead>
<tr>
<th>NH2-</th>
<th>N-SH2</th>
<th>PTP</th>
<th>COOH-</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 C5T</td>
<td>Thr2Ile</td>
<td>PVR, 3 HCM</td>
<td>1 HCM</td>
</tr>
<tr>
<td>2 A124G</td>
<td>Thr42Ala</td>
<td>1 PS</td>
<td>1 (arrhythmia)</td>
</tr>
<tr>
<td>3 T184G</td>
<td>Tyr62Asp</td>
<td>1 ASD</td>
<td>1 (familial)</td>
</tr>
<tr>
<td>4 C215G</td>
<td>Ala73Gly</td>
<td>1 ASD</td>
<td>3 (familial)</td>
</tr>
<tr>
<td>5 A317C</td>
<td>Asp106Ala</td>
<td>1 ASD</td>
<td>1 (familial)</td>
</tr>
<tr>
<td>6 PTP</td>
<td>Thr279Cys</td>
<td>1 PVS, 3 HCM</td>
<td>1 (familial)</td>
</tr>
<tr>
<td>7 A922G</td>
<td>Asn308Asp</td>
<td>6 PS (familial)</td>
<td>1 ASD</td>
</tr>
<tr>
<td>8 A923G</td>
<td>Asn308Ser</td>
<td>1 ASD</td>
<td>1 ASD</td>
</tr>
<tr>
<td>9 C1403T</td>
<td>Thr468Met</td>
<td>2 HCM, 1 AVCD</td>
<td>1 ASD</td>
</tr>
<tr>
<td>10 G1508C</td>
<td>Gly503Arg</td>
<td>1 PVS, 3 HCM</td>
<td>1 ASD</td>
</tr>
<tr>
<td>11 A1510G</td>
<td>Met504Val</td>
<td>1 ASD</td>
<td>1 ASD</td>
</tr>
<tr>
<td>12 C1678T</td>
<td>Leu560Phe</td>
<td>1 HCM</td>
<td>1 HCM</td>
</tr>
<tr>
<td>Total</td>
<td>14</td>
<td>14</td>
<td>20</td>
</tr>
</tbody>
</table>

*Known mutations.

ASD, atrial septal defect; AVCD, atrioventricular septal defect; COOH-, COOH terminal region; CSH2, C terminal SH 2 domain; HCM, hypertrophic cardiomyopathy; ML/LS, multiple lentigines/LEOPARD syndrome; MVA, mitral valve anomaly; NH2-, NH2 terminal region; N-SH2, N-terminal SH2 domain; PVR, pulmonary valve stenosis; PTP, phosphotyrosine phosphatase domain.

DISCUSSION

PTPN11 mutations are associated with a broad spectrum of congenital heart defects, both in Noonan syndrome and in ML/LS. This is consistent with animal models, which have suggested a pathogenic role of the SHP2 protein in semilunar valve and myocardial development. In the present study we have investigated possible correlations between PTPN11 mutations and clinical features, in particular cardiac defects. Pulmonary stenosis was the most common congenital heart defect in patients with Noonan syndrome and PTPN11 mutations. However, in contrast to a previous study, pulmonary stenosis had a similar frequency in patients with and without mutations. The association between pulmonary stenosis and codon 308 mutations could reflect the presence of a Noonan syndrome mutation hot spot in this position.
However, previous genotype-phenotype correlation studies, which recognised the mutation hot spot, did not establish such a correlation. Interestingly, in this cohort of patients, pulmonary stenosis was the only congenital heart defect associated with mutations in codon 308. In patients with PTPN11 mutations, pulmonary stenosis showed a distinct valve leaflet dysplasia (table 2), in agreement with evidence in mice. On the other hand, non-syndromic pulmonary stenosis without leaflet dysplasia is not related to PTPN11 mutations, suggesting that a different genetic background causes distinct pulmonary stenosis subtypes.

PTPN11 mutations occurred in eight of 12 patients with hypertrophic cardiomyopathy, without any obvious difference between individuals with and without mutations. The hypertrophic cardiomyopathy rate among ML/LS patients with mutations was higher than previously recognised and was clearly related to exon 7 and 12 mutations in the group of patients with mutations as a whole. Interestingly, all ML/LS individuals with hypertrophic cardiomyopathy who have been screened so far harboured a PTPN11 mutation. Hence, PTPN11 mutations are a major cause of hypertrophic cardiomyopathy in paediatric patients, mainly in the setting of ML/LS. However, the histological features of syndromic and non-syndromic hypertrophic cardiomyopathy are similar, and therefore PTPN11 could also be a candidate gene for isolated hypertrophic cardiomyopathy.

ASDs often occur in association with different malformation syndromes. Although our cohort of patients with Noonan syndrome and ASD was small, this defect was noticeably correlated with exon 3 mutations.

PTPN11 mutations were associated with partial AVCD in three patients, suggesting that mutations of this gene are responsible of a specific type of syndromic AVCD, similarly to chromosomal aneuploidies (that is, Down’s syndrome and deletion 8p syndrome) and other gene mutations (EVC gene in Ellis-van Creveld syndrome, DHCR7 in Smith-Lemli-Opitz syndrome, MKS gene in McKusick-Kaufman syndrome, and ZIC3 gene in X linked heterotaxia). As with ASD, MVA was also associated with an exon 3 mutation. It has been suggested that MVA in Noonan syndrome may be secondary to cardiac jelly and extracellular matrix defects, which are also likely to account for AVCD. Hence, myocardial and atriocentric valve involvement suggests a role for the PTPN11 gene in left ventricular differentiation and mesenchyme development of the atriocentric cushion.

None of patients harbouring PTPN11 gene mutations had coarctation of the aorta or other common congenital heart defects such as Fallot’s tetralogy or ventricular septal defects. Two ML/LS patients with PTPN11 mutations had conduction defects, which have also been detected in PTPN11 animal models. Even if the figure of 87% congenital heart defects in our present series was biased by cardiological recruitment criteria, only 37% of them had PTPN11 mutations. Other gene mutations could account for the heterogeneous cardiac phenotype in Noonan syndrome and ML/LS. Our study has shown that N-SH2 domain mutations are strictly associated with congenital heart defects, although in two Noonan syndrome families not all the affected family members had congenital heart disease. Intramalformal variability of the cardiac phenotype related to the A188G and A922G mutations points to a reduced penetrance, with a likely regulatory effect of other unknown genes and environmental agents.

The overall PTPN11 mutation detection rate was 40% (39% in sporadic and 50% in familial cases). This figure, which is reduced to 33% if only patients with Noonan syndrome are considered, is slightly lower than previously reported (45%). This difference could be explained by assuming that both deletions and missense mutations could have been overlooked by SSCP screening. However, Musante et al have also reported a superimposable rate of mutation in a wide cohort of patients with Noonan syndrome screened by DHPLC analysis. On the other hand, 85% of ML/LS patients had PTPN11 gene mutations, with two specific hot spots in the PTP domain. Thus PTPN11 can be considered the major gene

<table>
<thead>
<tr>
<th>Heart defects</th>
<th>Patients with PTPN11 mutations</th>
<th>Patients without PTPN11 mutations</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Noonan syndrome</td>
<td>ML/LS</td>
</tr>
<tr>
<td>Pulmonary valve stenosis</td>
<td>13*</td>
<td>1**</td>
</tr>
<tr>
<td>Hypertrophic cardiomyopathy</td>
<td>3</td>
<td>5</td>
</tr>
<tr>
<td>Atrial septal defect</td>
<td>2 (1‡)</td>
<td>0</td>
</tr>
<tr>
<td>Aortic coarctation</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Mitral valve anomaly</td>
<td>(1‡)</td>
<td>2</td>
</tr>
<tr>
<td>Atrioventricular canal defect</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Tetralogy of Fallot</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Ventricular septal defects</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>No congenital heart defect</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>Total</td>
<td>23</td>
<td>11</td>
</tr>
</tbody>
</table>

*Eleven with dysplastic leaflets.
**Nine with dysplastic leaflets.
††With dysplastic leaflets.
†With dysplastic leaflets.
‡Associated congenital heart defect.

Table 2 Spectrum of congenital heart defect of the 84 patients evaluated in the present study
of ML/LS." As previously reported, the differential diagnosis between these two syndromes may sometimes be difficult on clinical grounds alone, as specific ML/LS features can appear over the years in subjects diagnosed as having Noonan syndrome. In this respect, it would be of interest to follow up the Noonan patient reported by Tartaglia, who carried the A836G mutation that was found only in ML/LS individuals in the present and previous cohorts of patients. 31

In contrast to other reports, we also found that short stature in Noonan syndrome was significantly associated with PTPN11 mutations, supporting a role of SHP2 in linear growth, as shown by studies in murine models. 32

Conclusions
Pulmonary stenosis and hypertrophic cardiomyopathy are the prevailing congenital heart defects in Noonan syndrome and ML/LS associated with PTPN11 mutations. Different heart defects show correlations with the location of mutations within the PTPN11 gene, with statistically significant associations for pulmonary stenosis, hypertrophic cardiomyopathy, and ASD, which appear to cluster to distinct gene domains.

ACKNOWLEDGEMENTS
This study was supported in part by grants from the Italian Ministry of Health (RC 2002) and from the Italian Ministry of Instruction, University and Research (40% grant to BID). We thank Tania Dottorani and Giorgia Esposito for assistance.

REFERENCES